Pacira BioSciences, Inc.
PCRXNext catalyst
Enekinragene Inzadenovec (PCRX-201)
Osteoarthritis (OA) of the Knee
Get an email about PCRX's next catalysts
Track Pacira BioSciences (PCRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
Enekinragene Inzadenovec (PCRX-201) Phase 2 Est. Readout
Primary completion for Enekinragene Inzadenovec (PCRX-201) trial (NCT06884865) in Osteoarthritis (OA) of the Knee
SourceZILRETTA Phase 3 Est. Readout
Estimated primary completion for ZILRETTA trial (NCT06269705) in Glenohumeral Osteoarthritis. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
TCA IR 40
Osteoarthritis of the Knee
ZILRETTA
Glenohumeral Osteoarthritis
bupivacaine (HCl)
Total Ankle Arthroplasty
Liposomal bupivacaine
Surgery
Exparel
Postoperative Pain Management
Exparel Injectable Product
Coronary Artery Disease
Bupivacaine
Mammaplasty
SKY0402
Hemorrhoid
Bupivacaine liposome
Dental Pain
bupivacaine liposome injectable suspension
Pain
FX006
Osteoarthritis of the Knee
Bupivacaine Hydrochloride
Lower Extremity Surgery
Bupivacaine HCl
Postoperative Pain
Mid-dose SKY0402 + bupivacaine HCl
Postoperative Pain
FX005
Osteoarthritis, Knee
SKY0402 + bupivacaine HCl
Postoperative Pain
Enekinragene Inzadenovec (PCRX-201)
Osteoarthritis (OA) of the Knee
TCA IR
Osteoarthritis of the Knee
TAcs
Bilateral Knee Osteoarthritis
Liposome bupivacaine
Hallux Valgus (Bunions)
Liposome bupivacaine + bupivacaine
Dupuytren's Contracture of the Hand (Viking's Disease)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TCA IR 40 | Phase 3 | Osteoarthritis of the Knee | - | - |
ZILRETTA | Phase 3 | Glenohumeral Osteoarthritis | - | - |
bupivacaine (HCl) | Phase 3 | Total Ankle Arthroplasty | - | - |
Liposomal bupivacaine | Phase 3 | Surgery | - | - |
Exparel | Phase 3 | Postoperative Pain Management | - | - |
Exparel Injectable Product | Phase 3 | Coronary Artery Disease | - | - |
Bupivacaine | Phase 3 | Mammaplasty | - | - |
SKY0402 | Phase 3 | Hemorrhoid | - | - |
Bupivacaine liposome | Phase 3 | Dental Pain | - | - |
bupivacaine liposome injectable suspension | Phase 3 | Pain | - | - |
FX006 | Phase 3 | Osteoarthritis of the Knee | - | - |
Bupivacaine Hydrochloride | Phase 3 | Lower Extremity Surgery | - | - |
Bupivacaine HCl | Phase 3 | Postoperative Pain | - | - |
Mid-dose SKY0402 + bupivacaine HCl | Phase 2 | Postoperative Pain | - | - |
FX005 | Phase 2 | Osteoarthritis, Knee | - | - |
SKY0402 + bupivacaine HCl | Phase 2 | Postoperative Pain | - | - |
Enekinragene Inzadenovec (PCRX-201) | Phase 2 | Osteoarthritis (OA) of the Knee | - | - |
TCA IR | Phase 2 | Osteoarthritis of the Knee | - | - |
TAcs | Phase 2 | Bilateral Knee Osteoarthritis | - | - |
Liposome bupivacaine | Phase 2 | Hallux Valgus (Bunions) | - | - |
Liposome bupivacaine + bupivacaine | Phase 2 | Dupuytren's Contracture of the Hand (Viking's Disease) | - | - |
Frequently asked questions
What is in Pacira BioSciences, Inc.'s drug pipeline?→
CatalystAlert tracks 21 drug candidates in Pacira BioSciences, Inc.'s (PCRX) pipeline across Phase 3, Phase 2. Its lead program is ZILRETTA (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pacira BioSciences, Inc.'s next FDA catalyst?→
Pacira BioSciences, Inc.'s (PCRX) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PCRX biotech catalysts?→
Add PCRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pacira BioSciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.